Loading
A phase 2 trial of Fostamatinib in Diffuse large B-cell lymphoma, run by AstraZeneca, completed.
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer is a phase 2 interventional study registered as NCT01499303 by AstraZeneca, with 101 participants recorded, started 2011-12 and reaching its primary completion in 2013-10. Interventions recorded: Fostamatinib. Conditions recorded: Diffuse Large B-Cell Lymphoma.
Linked to the drug Fostamatinib because the registry names it among its interventions and Diffuse large B-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
101 enrolled.
95% CI 1.17 to 30.38; Figures from the ClinicalTrials.gov results section (first posted 2014-08-22), not from a publication · 95% CI 0.00 to 7.55
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rateprimary | 100mg BID | 21 | 2 participants | - | - | link |
| 200mg BID | 47 | 0 participants |
Shares Fostamatinib and the tag pipeline.
Shares Fostamatinib and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Diffuse large B-cell lymphoma and the tag pipeline.